CompletedNCT00997984
Morning or evening guanfacine for children with ADHD
About this title
Read the official source — NCT00997984Medication studyAges 6–12United States + Canada
Understand this study
Who was this study for?
Listed age limits: 6 years to 12 years.
- Listed locations
- Little Rock and 45 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: November 17, 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 340
- Sponsor
- Shire
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Canada
- Age range
- From 6 Years to 12 Years
- Official registry ID
- NCT00997984
- Official title
Show the full official title
A Phase 3, Double-blind, Randomized, Multicenter, Placebo-controlled, Dose Optimization Study Evaluating the Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children Aged 6-12 With a Diagnosis of Attention-Deficit/Hyperactivity Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Little Rock, United States · El Centro, United States · Rolling Hills Estates, United States
42 more locations
- San Diego, United States
- Wildomar, United States
- Bradenton, United States
- Gainesville, United States
- Jacksonville, United States
- Maitland, United States
- Orlando, United States
- West Palm Beach, United States
- Atlanta, United States
- Marietta, United States
- Boise, United States
- Chicago, United States
- Oak Brook, United States
- Indianapolis, United States
- Terre Haute, United States
- Overland Park, United States
- Paducah, United States
- New Orleans, United States
- Rockville, United States
- Rochester Hills, United States
- Saint Charles, United States
- Las Vegas, United States
- Toms River, United States
- Fargo, United States
- Oklahoma City, United States
- Philadelphia, United States
- Pittsburgh, United States
- Providence, United States
- Memphis, United States
- Austin, United States
- Houston, United States
- Lake Jackson, United States
- Lubbock, United States
- San Antonio, United States
- Burlington, United States
- Herndon, United States
- Richmond, United States
- Bellevue, United States
- Vancouver, Canada
- Toronto, Canada
- Whitby, Canada
- Saskatoon, Canada
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Shire.
Did this study involve medication?
Yes. The study involved medication, including extended-release guanfacine hydrochloride (SPD503), placebo and extended-release guanfacine hydrochloride.
Who was this study for?
Listed age limits: 6 years to 12 years.
